Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: Implications for human breast cancer

Molecular and Cellular Biology

Volumn 21, Issue 5, 2001, Pages 1540-1551

  Dankort, D ^a   Maslikowski, B ^a   Warner, N ^a   Kanno, N ^a   Kim, H ^a   Wang, Z ^a   Moran, M F ^a   Oshima, R G ^a   Cardiff, R D ^a   Muller, W J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; PROTEIN TYROSINE KINASE;

ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; BREAST CARCINOGENESIS; CELL SPECIFICITY; CELL TRANSFORMATION; DNA SYNTHESIS; EPITHELIUM CELL; GENE AMPLIFICATION; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ALLELES; ANIMALS; BINDING SITES; BREAST NEOPLASMS; CELL LINE; CHROMATOGRAPHY, AFFINITY; DNA-BINDING PROTEINS; FEMALE; GLUTATHIONE TRANSFERASE; GRB2 ADAPTOR PROTEIN; HUMANS; IMMUNOBLOTTING; KINETICS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM METASTASIS; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN STRUCTURE, TERTIARY; PROTEINS; PROTO-ONCOGENE PROTEIN C-ETS-2; PROTO-ONCOGENE PROTEINS; RAP1 GTP-BINDING PROTEINS; RATS; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TERMINAL REPEAT SEQUENCES; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

MUS MUSCULUS;

EID: 0035137171     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.5.1540-1551.2001     Document Type: Article

References (56)

1. Neu differentiation factor stimulates phosphorylation and activation of the Sp1 transcription factor
2. Amplification of neu/erbB-2 oncogene in a novel model of mammary tumorigenesis
3. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
4. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
5. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway
6. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene
7. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation
8. Reovirus therapy of tumors with activated Ras pathway
9. Distinct tyrosine autophosphorylation sites negatively and positively modulate Neu-mediated transformation
10. The carboxy-terminal domains of ErbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity
11. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
12. The ErbB-2 mitogenic signaling pathway: Tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with ErbB-2 mitogenic potency
13. Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3
14. Oneogenic Neu/ ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation
15. A point mutation in the MET oncogene abrogates metastasis without affecting transformation
16. A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3
17. Tyrosine phosphorylation sites at amino acids 239 and 240 of Shc are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activatecl protein kinase activation
18. Activated neu induces rapid tumor progression
19. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
20. Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with Ras-dependent activation of Raf-1
21. The biology of erbB-2/neu/HER-2 and its role in cancer
22. Activation of C3G guanine nucleotide exchange factor for Rap1 by phosphorylation of tyrosine 504
23. Activation of the Drosophila C3G leads to cell fate changes and overproliferation during development, mediated by the RAS-MAPK pathway and RAP1
24. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2
25. Reversion of middle T antigen-transformed Rat-2 cells by Krev-1: Implications for the role of p21c-ras in polyomavirus-mediated transformation
26. Genetic analysis of the Kirsten-ras-revertant 1 gene: Potentiation of its tumor suppressor activity by specific point mutations
27. Involvement of pp60c-src with two major signaling pathways in human breast cancer
28. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development
29. Ras effectors
30. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
31. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo
32. Activation of the Src family of tyrosine kinases in mammary tumorigenesis
33. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor
34. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity
35. The ErbB signaling network: Receptor heterodimerization in development and cancer
36. Protein modules and signalling networks
37. Analysis of protein-protein interactions involved in the activation of the Sbc/Grb-2 pathway by the ErbB-2 kinase
38. smg/rap1/Krev-1 p21s inhibit the signal pathway to the c-fos promoter/enhancer from c-Ki-ras p21 but not from c-raf-1 kinase in NIH3T3 cells
39. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene
40. erb-2 determine the specificity of signal transduction
41. Shc products are substrates of erbB-2 kinase
42. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors
43. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: Implications for human breast cancer
44. Human breast cancer: Correlation of relapse and survival with the amplification of the HER2/neu oneogene
45. Studies of the HER-2/neu proto-oncogene in human breast and ovaian cancer
46. The SH2 protein GRB7 is coamplified, overexpressed and in a tight complex with HER2 in breast cancer
47. Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates cellular transformation
48. Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal
49. The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/ 240) that mediate protein-protein interactions
50. Lobulo-alveolar development of mouse mammary glands is regulated by thyroid hormones
51. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3
52. Requirement for the adapter protein GRB2 in EGF receptor endocytosis
53. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene
54. Requirement for both Shc and phosphatidylinositol 3′kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis
55. Defective trophoblast function in mice with a targeted mutation of Ets2
56. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2